D. Boral Capital Reiterates "Buy" Rating for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ:URGN - Get Free Report)'s stock had its "buy" rating reissued by D. Boral Capital in a report issued on Thursday,Benzinga reports. They currently have a $25.00 price target on the stock. D. Boral Capital's price target would indicate a potential upside of 141.55% from the company's current price.

A number of other equities analysts have also recently issued reports on the company. Scotiabank initiated coverage on UroGen Pharma in a report on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $55.00 target price on shares of UroGen Pharma in a research note on Monday, April 28th. The Goldman Sachs Group decreased their price target on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price objective on the stock. Finally, Guggenheim reaffirmed a "buy" rating on shares of UroGen Pharma in a research report on Tuesday, April 29th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $32.86.

UroGen Pharma Trading Down 3.0 %

URGN traded down $0.32 during mid-day trading on Thursday, reaching $10.35. The stock had a trading volume of 502,562 shares, compared to its average volume of 542,364. The firm's fifty day simple moving average is $10.64 and its two-hundred day simple moving average is $10.98. The stock has a market capitalization of $477.21 million, a P/E ratio of -3.29 and a beta of 0.66. UroGen Pharma has a 52 week low of $8.94 and a 52 week high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to analysts' expectations of $25.25 million. On average, equities analysts predict that UroGen Pharma will post -3.12 EPS for the current year.

Institutional Investors Weigh In On UroGen Pharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. RTW Investments LP boosted its stake in shares of UroGen Pharma by 1.3% during the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company's stock worth $40,841,000 after acquiring an additional 47,447 shares during the period. Toronto Dominion Bank acquired a new stake in UroGen Pharma during the 4th quarter valued at $18,628,000. Vestal Point Capital LP increased its holdings in shares of UroGen Pharma by 307.5% in the fourth quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company's stock valued at $17,360,000 after purchasing an additional 1,230,000 shares during the last quarter. Acorn Capital Advisors LLC acquired a new position in shares of UroGen Pharma in the fourth quarter valued at $16,149,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of UroGen Pharma by 2.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company's stock valued at $14,667,000 after purchasing an additional 36,084 shares during the period. 91.29% of the stock is owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.